Midatech Creates PharMida AG, A New Subsidiary Applying Nanotechnology to Drug Discovery
Midatech, a company that focuses on the design, synthesis, and manufacture of biocompatible nanoparticles, recently announced the formation of a Basel-based Swiss drug development subsidiary, PharMida AG. The subsidiary follows an important investment by a group of Switzerland-based investors into Midatech Ltd. The mission of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. PharMida will have the responsibility to project manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage the collection of the already existing Midatech Ltd product lines in Life Sciences.